FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a KMT2A Translocation By Ogkologos - December 10, 2024 723 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AUGMENT-101 study Source RELATED ARTICLESMORE FROM AUTHOR Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type Population-based lung cancer screening can reduce mortality in people who have never smoked, study shows in China EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib MOST POPULAR New Approach Uses Much Less Tissue to Analyze Tumor Proteins and... February 27, 2020 Επικοινωνία January 18, 2019 Foodie Friday: Pumpkin EVERYTHING! October 8, 2021 How I Navigated the Challenges of 2 Colorectal Cancer Diagnoses As... January 6, 2022 Load more HOT NEWS How to Cope With Taking Long-Term Medication The Evidence Is In: COVID Vaccines Do Protect Patients With Cancer... Five Questions With…Keon. Adjuvant Capecitabine-Containing Regimen Improves Modestly Overall Survival in Patients with Early...
